NCI-H2122、H2122、NCI-H2122细胞、H2

NCI-H2122、H2122、NCI-H2122细胞、H2122细胞、NCI-H2122人非小细胞肺癌细胞

Cell line name NCI-H2122

Synonyms H2122; H-2122; NCIH2122

Accession CVCL_1531

Resource Identification Initiative To cite this cell line use: NCI-H2122 (RRID:CVCL_1531)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Population: Caucasian.

Doubling time: 27 hours (PubMed=25984343); 31.6 hours (PubMed=29681454).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

Sequence variations

Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP=722046; DepMap=ACH-000311).

Mutation; HGNC; 11998; TP53; Simple; p.Gln16Leu (c.47A>T); Zygosity=Heterozygous (PubMed=20557307; Cosmic-CLP=722046; DepMap=ACH-000311).

Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Heterozygous (PubMed=20557307; Cosmic-CLP=722046; DepMap=ACH-000311).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*01:01,03:01

HLA-B B*07:02,08:01

HLA-C C*07:01,07:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0

Native American 0.26

East Asian, North 1.42

East Asian, South 0

South Asian 1.39

European, North 65.92

European, South 31.01

Disease Lung adenocarcinoma (NCIt: C3512)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Originate from same individual CVCL_2651 ! NCI-BL2122

Sex of cell Female

Age at sampling 46Y

Category Cancer cell line

STR profile Source(s): AddexBio=C0016048/5013; ATCC=CRL-5985; Cosmic-CLP=722046; PubMed=25877200

 

Markers:

Amelogenin X

CSF1PO 10

D2S1338 17

D3S1358 15,16

D5S818 11,12

D7S820 8,10

D8S1179 13

D13S317 10

D16S539 9,12

D18S51 19

D19S433 14

D21S11 33.2

FGA 19,26

Penta D 10,12

Penta E 11,14

TH01 7,9.3

TPOX 9

vWA 17

 

Run an STR similarity search on this cell line

Publications

PubMed=1311061

Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D., Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Oncogene 7:171-180(1992)

 

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. Suppl. 24:32-91(1996)

 

PubMed=10987304

Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.

Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Cancer Res. 60:4894-4906(2000)

 

PubMed=11030152; DOI=10.1038/sj.onc.1203815

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Oncogene 19:4632-4639(2000)

 

PubMed=11314036; DOI=10.1038/sj.onc.1204211

Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Oncogene 20:1005-1009(2001)

 

PubMed=16157194; DOI=10.1016/j.cancergencyto.2005.03.007

Grigorova M., Lyman R.C., Caldas C., Edwards P.A.W.

Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping.

Cancer Genet. Cytogenet. 162:1-9(2005)

 

PubMed=16187286; DOI=10.1002/ijc.21491

Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D., Gazdar A.F., Lam S., MacAulay C., Lam W.L.

High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.

Int. J. Cancer 118:1556-1564(2006)

 

PubMed=18083107; DOI=10.1016/j.cell.2007.11.025

Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Cell 131:1190-1203(2007)

 

PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846

Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

A gene-alteration profile of human lung cancer cell lines.

Hum. Mutat. 30:1199-1206(2009)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Cancer Sci. 101:1891-1896(2010)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)